Human papillomavirus vaccine TA-CIN - Cancer Research Technology

Drug Profile

Human papillomavirus vaccine TA-CIN - Cancer Research Technology

Alternative Names: TA-CIN; Therapeutic HPV vaccine - Cancer Research Technology

Latest Information Update: 29 Jul 2015

Price : $50

At a glance

  • Originator Xenova Group
  • Class Cancer vaccines; Papillomavirus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Human papillomavirus infections

Highest Development Phases

  • Phase II Vulvar intraepithelial neoplasia
  • Phase I Cervical dysplasia

Most Recent Events

  • 29 Jul 2015 TA-CIN is still in active development with non-industrial organisations
  • 31 May 2007 Further phase II clinical trials are planned for the vaccine
  • 13 Jan 2005 TA-CIN has been licensed to Cancer Research Technology for onward licensing and development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top